This Week in Startups cover image

Genomes Unlocked: Anne Wojcicki's Vision for 23andMe and the Future of Proactive Healthcare | E1858

This Week in Startups

NOTE

The Potential of Drug Discovery and Therapeutics in the Biotech Business

23Me has two programs in drug discovery, focused on immuno-oncology. They analyze existing drugs and genetic data to find similar signatures. They have a partnership with GSK and a dedicated drug discovery team. They believe in managing what you can and using therapeutics for what you can't control. The business has a profitable consumer side and a potentially explosive drug business. They're open to partnerships to manage the burn rate.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner